REC-7735 (PI3Ka H1047R)
Recursion Pharmaceuticals: company profile
Phase 1/2 registry
Since , the date of the source that reports this phase.
Summary
REC-7735 is a PI3Ka H1047R from Recursion Pharmaceuticals. The source describes it as small molecule. It is being developed for solid tumors (PI3Ka H1047R-mutant; breast cancer focus per earlier pipeline updates). ClinicalTrials.gov lists it at Phase 1/2 (recruiting) under NCT07819136. The AI role named in the source is molecule design. Registry records: NCT07819136, Phase 1/2, recruiting, updated Sep 29, 2026. About the company, based in United States: Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design. The latest dated source is from Sep 14, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Recursion Pharmaceuticals
- Indication
- Solid tumors (PI3Ka H1047R-mutant; breast cancer focus per earlier pipeline updates)
- Therapeutic area
- Oncology
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Phase 1/2, as of Sep 29, 2026
- Phase source
- Registry
- Board column
- Phase 1
Key readouts in the source
None; registry lists study as recruiting.
AI evidence
AI source: Company
“REC-7735, Recursion’s AI-designed PI3Kα H1047R inhibitor, was built to improve therapeutic index for a validated oncology target”
Trial records
- NCT07819136 on ClinicalTrials.gov (opens in new tab) Phase 1/2 Recruiting Updated
Milestone timeline
-
ClinicalTrials.gov record: Phase 1/2
None; registry lists study as recruiting.
-
NCT07819136 first posted on ClinicalTrials.gov
-
NCT07819136 record updated
Phase 1/2, Recruiting
About Recursion Pharmaceuticals
Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design.
Spot an error? Tell me and I'll fix it.